Compare Adaptive Biotechnologies Corp (ADPT) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Mondaycom Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Mondaycom Ltd trades at $81.2 (market cap $3.61B). The key difference: Adaptive Biotechnologies Corp and Mondaycom Ltd are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| ADPT | MNDY | |
|---|---|---|
Market Cap | $3.33B | $3.61B |
Sector | Health | Technology |
52-Week High | $22.37 | $309.62 |
52-Week Low | $10.24 | $58.81 |
Enterprise Value | $3.19B | $2.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Monday.com (MNDY) trades at $82.50, up 3.42% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $1.15 vs. $0.96 expected) and impressive 89% gross margins. Recent news highlights institutional interest despite some insider selling, while technical indicators suggest the stock is approaching resistance at $84.
The outlook remains positive with a $116.75 consensus price target (41% upside potential), though risks include high valuation multiples (P/E 36, EV/EBITDA 111) and projected negative cash flow in 2026. Revenue growth stability at 9%+ net margins supports the bullish case, but investors should monitor competitive pressures in the SaaS sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
